Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Healthcare Plans

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations and stop loss insurance. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Revenue projections:

Revenue projections for CI
Revenue projections for CI

CI's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.84900
forwardPE 8.74791
debtToEquity 75.13700
earningsGrowth -0.09300
revenueGrowth 0.10400
grossMargins 0.09298
operatingMargins 0.03530
trailingEps 22.19000
forwardEps 33.41598

With both earnings and revenue growth in low territory, The Cigna Group is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
CI's negative gross and operating margins suggest that the company is experiencing losses at both the production and operational levels. This could point to inefficiencies or declining demand for its products.
CI's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting CI to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for CI
Price projections for CI

The Cigna Group's present price relative to projections does not indicate any obvious risks or opportunities. This balanced situation suggests a period of stability, where investors may find it prudent to maintain their current strategies until more information becomes available.

Insider Transactions:

Insider Transactions for CI
Insider Transactions for CI


There were 6 The Cigna Group sales transactions, at market price of 307.3566640218099.1 purchases of The Cigna Group stock were recorded, with market price of 258.6199951171875 per share.Increased sells at CI's current price levels point to a possible decline. If this trend of selling continues, it may signal that the stock's price will face further downward pressure, reflecting investor concerns.

Recommendation changes over time:

Recommendations trend for CI
Recommendations trend for CI


Analysts have been favoring CI with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning CI as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.